SAN FRANCISCO -- (BUSINESS WIRE) -- ClinStar, LLC, an established clinical research organization providing clinical development services in the emerging markets of Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today that ClinStar will present on “Optimizing Time and Money in Clinical Trials by Including Russia and Eastern Europe” at Outsourcing Clinical Trials East Coast followed later the same week with a live webinar entitled, “Evaluating Clinical Trial Quality in Russia and Ukraine Compared to the West and Other Emerging Markets.”
President and CEO David Passov will present at Arena International’s 4th Annual Outsourcing in Clinical Trials East Coast conference March 19-20 on “Optimizing Time and Money in Clinical Trials by Including Russia and Eastern Europe.” During the presentation, Mr. Passov will discuss how to achieve optimal benefits when including Russia and Eastern Europe and present a case study that demonstrates actual operational and opportunity cost savings when conducting trials in this region. According to Mr. Passov, “With enrollment rates up to 20 times faster than in the West, the lure of conducting clinical trials in emerging markets such as Russia and Eastern Europe is undeniable. The greatest benefit to the drug development industry, however, is how working in this region translates into operational and opportunity cost savings, and ultimately, whether or not their drugs are receiving final regulatory approval.”
Additionally, Mr. Passov and Director QA Dr. Stanislav Gneushev will host a live webinar later the same week at 11:00 am ET March 22 entitled, “Evaluating Clinical Trial Quality in Russia and Ukraine Compared to the West and Other Emerging Markets.” During the webinar, Mr. Passov and Dr. Gneushev will evaluate the quality of clinical trials being conducted in Russia and Ukraine as compared to Western Europe, Eastern Europe and other Emerging Markets based on the results of recent FDA inspections conducted at clinical trial sites in these regions. In addition, they will examine the key criteria for ensuring overall high clinical trial quality.
ClinStar is one of the most prominent clinical research organizations in the emerging markets of Russia and Eastern Europe with more than 13 years of expertise in Phase I-IV clinical development in multiple therapeutic areas. Headquartered near San Francisco, California, ClinStar manages clinical trials from its offices in Russia, Ukraine and Belarus, with total staff of over 275 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.